Quote | Options | News | Analyst Ratings

Last: 5.05

Change: ($0.04)

Percent Change: -0.79

Volume: 33,321

Celldex Therapeutics, Inc. (Celldex) is a biopharmaceutical company, which applies its Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. The Company?s immunotherapy platform includes a portfolio of monoclonal antibodies, antibody-targeted vaccines, antibody-drug conjugates and immunomodulators to create disease-specific drug candidates. Its collaborations include the commercialization of an oral human rotavirus vaccine and the development of oncology and infectious disease vaccines. On October 1, 2009, Celldex acquired CuraGen Corporation.

8:00:01 AM 7/29/2010
Celldex Therapeutics to Report Second Quarter 2010 Financial Results on August 4, 2010
NEEDHAM, Mass., Jul 29, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (CLDX) will release its second quarter 2010 financial results before U.S. financial markets open on Wednesday, August 4, 2010. Celldex executives will host a conference call at 10:00 A.M. Eastern Time on the same day to provide an update on anticipated research and development and business objectives for 2010. Linda T. Vahdat, M.D., Director of the Breast Cancer Research Program and Professor of Medicine at Weill Medical College of Cornell University, will join the call. Dr. Vahdat is a leading investigator in the development of new therapies for breast cancer and was an important leader in Celldex's Phase 1/2 study of CDX-011 in advanced breast cancer.

10:47:00 AM 7/19/2010
In First Year Mentor Capital Cancer Immunotherapy Index Gains are Triple that of the Overall Market Appreciation
SAN DIEGO, Jul 19, 2010 (BUSINESS WIRE) -- Mentor Capital, Inc. (Pink Sheets:MNTR) reports that its Cancer Immunotherapy Index has appreciated 50.04% during the twelve months since its creation on July 10, 2009. This rate of gain is 339% of the average gain of the Dow Jones Industrials (15.48%), S&P 500 (13.24%) and NASDAQ Composite (15.50%) during the similar four quarter period.

9:00:04 AM 6/7/2010
Celldex Therapeutics Presents New Clinical Data from Phase 2 Study of CDX-011 in Metastatic Melanoma at 46th Annual ASCO Meeting
CHICAGO, Jun 07, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced the presentation of promising clinical data on CDX-011 in metastatic melanoma at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago, Illinois. The Phase 2 study has met its primary endpoint and the results support additional studies in this indication. CDX-011 is an antibody-drug conjugate (ADC) in Phase 2 development for the treatment of melanoma and advanced breast cancer. In addition, in a separate presentation today at ASCO, the Company presented the study design for its recently initiated Phase 2 trial of CDX-1307 in bladder cancer. CDX-1307 is an antibody-based cancer vaccine candidate and is being evaluated as a treatment for bladder cancer.

3:00:00 PM 6/5/2010
Celldex Therapeutics Presents Positive Results from Phase 1/2 Advanced Breast Cancer Study with CDX-011 at 46th Annual ASCO Meeting
CHICAGO, Jun 05, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that mature results from a Phase 1/2 study evaluating CDX-011 in advanced stage breast cancer patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). CDX-011 is an experimental antibody-drug conjugate (ADC) directed against glycoprotein NMB (GPNMB) and linked to a potent cancer cell-killing drug, monomethyl-auristatin E (MMAE).

9:00:01 AM 6/5/2010
Interim Positive Results From Phase 2b Brain Cancer Study With Rindopepimut (PF-04948568 or CDX-110) Presented at 46th Annual ASCO Meeting
CHICAGO, Jun 05, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that interim results from a Phase 2b study evaluating rindopepimut (formerly PF-04948568 or CDX-110) in newly-diagnosed glioblastoma multiforme (GBM) patients were presented at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Rindopepimut, an investigational immunotherapeutic vaccine that targets the tumor-specific molecule epidermal growth factor receptor variant III (EGFRvIII), was developed by Celldex Therapeutics and is licensed to Pfizer.

9:48:01 AM 6/3/2010
Celldex Therapeutics to Present at Upcoming Investor Conferences in New York City
NEEDHAM, Mass., Jun 03, 2010 (BUSINESS WIRE) -- Celldex Therapeutics, Inc. (CLDX) today announced that Anthony S. Marucci, President and Chief Executive Officer of Celldex Therapeutics, Inc., will present at the following investor conferences: